The Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice
Praxis (Bern 1994). 2023;112(4):199-204. doi: 10.1024/1661-8157/a003990.ABSTRACTThe Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice Abstract. The use of combined hormonal contraceptives (CHC) increases not only the risk for venous thromboembolism, but also for arterial thromboembolism. The risk for thromboembolism is the same for non-oral CHC (patches, vaginal rings) as for oral CHC. Risk factors such as age >35, obesity, smoking and a positive family history need to be recognized and considered in contraceptive counselling. Elaborate information concerning risks and b...
Source: Praxis - March 15, 2023 Category: General Medicine Authors: Dorothea Wunder Source Type: research
The Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice
Praxis (Bern 1994). 2023;112(4):199-204. doi: 10.1024/1661-8157/a003990.ABSTRACTThe Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice Abstract. The use of combined hormonal contraceptives (CHC) increases not only the risk for venous thromboembolism, but also for arterial thromboembolism. The risk for thromboembolism is the same for non-oral CHC (patches, vaginal rings) as for oral CHC. Risk factors such as age >35, obesity, smoking and a positive family history need to be recognized and considered in contraceptive counselling. Elaborate information concerning risks and b...
Source: Praxis - March 15, 2023 Category: General Medicine Authors: Dorothea Wunder Source Type: research
The Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice
Praxis (Bern 1994). 2023;112(4):199-204. doi: 10.1024/1661-8157/a003990.ABSTRACTThe Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice Abstract. The use of combined hormonal contraceptives (CHC) increases not only the risk for venous thromboembolism, but also for arterial thromboembolism. The risk for thromboembolism is the same for non-oral CHC (patches, vaginal rings) as for oral CHC. Risk factors such as age >35, obesity, smoking and a positive family history need to be recognized and considered in contraceptive counselling. Elaborate information concerning risks and b...
Source: Praxis - March 15, 2023 Category: General Medicine Authors: Dorothea Wunder Source Type: research
The Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice
Praxis (Bern 1994). 2023;112(4):199-204. doi: 10.1024/1661-8157/a003990.ABSTRACTThe Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice Abstract. The use of combined hormonal contraceptives (CHC) increases not only the risk for venous thromboembolism, but also for arterial thromboembolism. The risk for thromboembolism is the same for non-oral CHC (patches, vaginal rings) as for oral CHC. Risk factors such as age >35, obesity, smoking and a positive family history need to be recognized and considered in contraceptive counselling. Elaborate information concerning risks and b...
Source: Praxis - March 15, 2023 Category: General Medicine Authors: Dorothea Wunder Source Type: research
The Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice
Praxis (Bern 1994). 2023;112(4):199-204. doi: 10.1024/1661-8157/a003990.ABSTRACTThe Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice Abstract. The use of combined hormonal contraceptives (CHC) increases not only the risk for venous thromboembolism, but also for arterial thromboembolism. The risk for thromboembolism is the same for non-oral CHC (patches, vaginal rings) as for oral CHC. Risk factors such as age >35, obesity, smoking and a positive family history need to be recognized and considered in contraceptive counselling. Elaborate information concerning risks and b...
Source: Praxis - March 15, 2023 Category: General Medicine Authors: Dorothea Wunder Source Type: research
The Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice
Praxis (Bern 1994). 2023;112(4):199-204. doi: 10.1024/1661-8157/a003990.ABSTRACTThe Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice Abstract. The use of combined hormonal contraceptives (CHC) increases not only the risk for venous thromboembolism, but also for arterial thromboembolism. The risk for thromboembolism is the same for non-oral CHC (patches, vaginal rings) as for oral CHC. Risk factors such as age >35, obesity, smoking and a positive family history need to be recognized and considered in contraceptive counselling. Elaborate information concerning risks and b...
Source: Praxis - March 15, 2023 Category: General Medicine Authors: Dorothea Wunder Source Type: research
The Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice
Praxis (Bern 1994). 2023;112(4):199-204. doi: 10.1024/1661-8157/a003990.ABSTRACTThe Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice Abstract. The use of combined hormonal contraceptives (CHC) increases not only the risk for venous thromboembolism, but also for arterial thromboembolism. The risk for thromboembolism is the same for non-oral CHC (patches, vaginal rings) as for oral CHC. Risk factors such as age >35, obesity, smoking and a positive family history need to be recognized and considered in contraceptive counselling. Elaborate information concerning risks and b...
Source: Praxis - March 15, 2023 Category: General Medicine Authors: Dorothea Wunder Source Type: research
The Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice
Praxis (Bern 1994). 2023;112(4):199-204. doi: 10.1024/1661-8157/a003990.ABSTRACTThe Thromboembolism Risk with Combined Hormonal Contraceptives: Current Status and Prescribing Practice Abstract. The use of combined hormonal contraceptives (CHC) increases not only the risk for venous thromboembolism, but also for arterial thromboembolism. The risk for thromboembolism is the same for non-oral CHC (patches, vaginal rings) as for oral CHC. Risk factors such as age >35, obesity, smoking and a positive family history need to be recognized and considered in contraceptive counselling. Elaborate information concerning risks and b...
Source: Praxis - March 15, 2023 Category: General Medicine Authors: Dorothea Wunder Source Type: research
Association between preconception anti-androgen therapy and pregnancy outcomes of patients with PCOS: A prospective cohort study
ConclusionOur findings suggest that preconception androgen-lowering therapy in patients with PCOS improves pregnancy outcomes and reduces neonatal complications. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - January 30, 2023 Category: Endocrinology Source Type: research
Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha
Progestins, synthetic compounds designed to mimic the activity of natural progesterone (P4), are used globally in menopausal hormone therapy. Although the older progestins medroxyprogesterone acetate (MPA) and norethisterone (NET) have been implicated in increased breast cancer risk, little is known regarding newer progestins, and no significant risk has been associated with P4. Considering that breast cancer is the leading cause of mortality in women, establishing which progestins increase breast cancer incidence and elucidating the underlying mechanisms is a global priority. We showed for the first time that the newer-ge...
Source: Frontiers in Endocrinology - September 15, 2022 Category: Endocrinology Source Type: research
Drug ‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)
AbstractThe capsid assembly modulator JNJ-56136379 (bersacapavir) disrupts hepatitis B virus replication. It is metabolized via cytochrome P450 (CYP) 3A, but little is known about the drug-drug interactions of JNJ-56136379 when combined with drugs that inhibit or are metabolized by CYP3A. In a phase 1, open-label trial (NCT03945539), healthy adults received 1 dose of JNJ-56136379 with and without 21 days of prior exposure to itraconazole 200 mg (CYP3A inhibitor). In a second phase 1, open-label trial (NCT03111511), healthy women received 1 dose of drospirenone/ethinyl estradiol and midazolam before and after 15 days of JNJ...
Source: Clinical Pharmacology in Drug Development - September 5, 2022 Category: Drugs & Pharmacology Authors: Joris Vandenbossche,
Jeysen Yogaratnam,
Vera Hillewaert,
Freya Rasschaert,
Willem Talloen,
Jeike Biewenga,
Jan Snoeys,
Thomas N. Kakuda,
Martyn Palmer,
Julius Nangosyah,
Michael Biermer Tags: Original Article Source Type: research
Estetrol/Drospirenone: A Review in Oral Contraception
AbstractEstetrol/drospirenone is a combined oral contraceptive (COC) with a plant-synthesised foetal oestrogen (estetrol) and a well-established progestin (drospirenone). In preclinical models, estetrol has lower binding affinity for the oestrogen receptor- α (ER-α) in contrast to estradiol and has antagonistic properties against membrane ER-α in several tissues, including the breast, while retaining agonistic activity on receptors located in the nucleus. The low oestrogenicity of estetrol may potentially contribute to reduced thrombotic risk. Estet rol/drospirenone was an effective contraceptive in phase II and III cli...
Source: Drugs - July 4, 2022 Category: Drugs & Pharmacology Source Type: research
Development of a Translational Exposure-Bracketing Approach to Streamline the Development of Hormonal Contraceptive Drug Products
Clin Pharmacol Ther. 2022 Jun 20. doi: 10.1002/cpt.2690. Online ahead of print.ABSTRACTWorldwide, 922 million women of reproductive age (or their partners) use some sort of contraception to prevent pregnancy. Oral combined hormonal contraceptives (CHC) typically utilize a combination of a progestin and an estrogen. CHC are potentially at risk to metabolic drug-drug interaction (DDI) via CYP3A4, the main enzyme involved in the oxidative metabolism of ethinyl estradiol (EE) and most progestins, e.g. levonorgestrel (LNG) and drospirenone (DRSP). Recently, the FDA issued a guidance addressing metabolic DDIs in the realm of CHC...
Source: Clinical Pharmacology and Therapeutics - June 20, 2022 Category: Drugs & Pharmacology Authors: Brian Cicali Lais Da Silva Amir Sarayani Karthik Lingineni Michelle Pressly Soyoung Kim Thomas Wendl Joachim Hoechel Valvanera Vozmediano Almut G Winterstein Joshua D Brown Stephan Schmidt Rodrigo Cristofoletti Source Type: research
